Glycans pave the way for immunotherapy in triple-negative breast cancer

Autores
Girotti, Maria Romina; Salatino, Mariana; Rabinovich, Gabriel Adrián
Año de publicación
2018
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment. The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment.
Fil: Girotti, Maria Romina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Salatino, Mariana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Rabinovich, Gabriel Adrián. Universidad de Buenos Aires; Argentina
Materia
GLYCANS
BREAST CANCER
CANCER
POLYSACCHARIDES
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/89502
Acceder
id CONICETDig_82a57c185c8c970b4d7dd1f4659b6b6b
oai_identifier_str oai:ri.conicet.gov.ar:11336/89502
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Glycans pave the way for immunotherapy in triple-negative breast cancerGirotti, Maria RominaSalatino, MarianaRabinovich, Gabriel AdriánGLYCANSBREAST CANCERCANCERPOLYSACCHARIDEShttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment. The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment.Fil: Girotti, Maria Romina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Salatino, Mariana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Rabinovich, Gabriel Adrián. Universidad de Buenos Aires; ArgentinaCell Press2018-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/89502Girotti, Maria Romina; Salatino, Mariana; Rabinovich, Gabriel Adrián; Glycans pave the way for immunotherapy in triple-negative breast cancer; Cell Press; Cancer Cell; 33; 2; 2-2018; 155-1571535-6108CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.cell.com/cancer-cell/fulltext/S1535-6108(18)30015-1info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ccell.2018.01.015info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:00:29Zoai:ri.conicet.gov.ar:11336/89502instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:00:29.422CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Glycans pave the way for immunotherapy in triple-negative breast cancer
title Glycans pave the way for immunotherapy in triple-negative breast cancer
spellingShingle Glycans pave the way for immunotherapy in triple-negative breast cancer
Girotti, Maria Romina
GLYCANS
BREAST CANCER
CANCER
POLYSACCHARIDES
title_short Glycans pave the way for immunotherapy in triple-negative breast cancer
title_full Glycans pave the way for immunotherapy in triple-negative breast cancer
title_fullStr Glycans pave the way for immunotherapy in triple-negative breast cancer
title_full_unstemmed Glycans pave the way for immunotherapy in triple-negative breast cancer
title_sort Glycans pave the way for immunotherapy in triple-negative breast cancer
dc.creator.none.fl_str_mv Girotti, Maria Romina
Salatino, Mariana
Rabinovich, Gabriel Adrián
author Girotti, Maria Romina
author_facet Girotti, Maria Romina
Salatino, Mariana
Rabinovich, Gabriel Adrián
author_role author
author2 Salatino, Mariana
Rabinovich, Gabriel Adrián
author2_role author
author
dc.subject.none.fl_str_mv GLYCANS
BREAST CANCER
CANCER
POLYSACCHARIDES
topic GLYCANS
BREAST CANCER
CANCER
POLYSACCHARIDES
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment. The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment.
Fil: Girotti, Maria Romina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Salatino, Mariana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Rabinovich, Gabriel Adrián. Universidad de Buenos Aires; Argentina
description The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment. The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment.
publishDate 2018
dc.date.none.fl_str_mv 2018-02
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/89502
Girotti, Maria Romina; Salatino, Mariana; Rabinovich, Gabriel Adrián; Glycans pave the way for immunotherapy in triple-negative breast cancer; Cell Press; Cancer Cell; 33; 2; 2-2018; 155-157
1535-6108
CONICET Digital
CONICET
url http://hdl.handle.net/11336/89502
identifier_str_mv Girotti, Maria Romina; Salatino, Mariana; Rabinovich, Gabriel Adrián; Glycans pave the way for immunotherapy in triple-negative breast cancer; Cell Press; Cancer Cell; 33; 2; 2-2018; 155-157
1535-6108
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.cell.com/cancer-cell/fulltext/S1535-6108(18)30015-1
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ccell.2018.01.015
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Cell Press
publisher.none.fl_str_mv Cell Press
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269640775958528
score 13.13397

Publicaciones similares